Showing 71-80 of 454 results
Helsinn is delighted to be able to support this event at the leading congress for supportive cancer care and to participate in a discussion about how to support patients, doctors and caregivers in making informed choices in this important treatment area.
This exclusive agreement builds on broad partnerships with Mundipharma in cancer supportive care across multiple global territories
Anamorelin is a novel ghrelin receptor agonist, in development for the treatment of cancer anorexia-cachexia syndrome
Helsinn, a Swiss Group focused on building quality cancer care, announced today that additional study results from the ROMANA Phase III program were presented at the International Association for the Study of Lung Cancer’s 16th World Conference on Lung Cancer (WCLC), taking place in Denver from 06 September to 09 September, 2015.
Launch of Netupitant-Palonosetron Fixed Combination (Akynzeo®) in the UK by Chugai Pharma UK Ltd
The prestigious accreditation recognizes Helsinn’s commitment to reducing cancer risk through the promotion of healthier lifestyle, earlier disease detection and high quality care in the workplace
Helsinn Healthcare SA announces that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. to resolve certain patent litigations relating to Helsinn Healthcare's Aloxi® (palonosetron HCl injection) in the United States, where it is currently distributed by Helsinn Healthcare's marketing partner, Eisai Inc.
Helsinn Group announces that AKYNZEO® (netupitant/palonosetron) has been nominated by the Galien Foundation within the category "Best Pharmaceutical Agent of the Year" at the ninth annual Prix Galien USA Awards.
Helsinn Group and Eisai Inc. announced today that the American Society of Clinical Oncology (ASCO) has published a focused update to its clinical practice guidelines for antiemetics in oncology recognizing AKYNZEO® (netupitant/palonosetron) as an additional option for the prevention of acute and delayed nausea and vomiting in patients receiving highly-emetogenic chemotherapy re...
Helsinn Group announced today that the U.S. District Court for the District of New Jersey has ruled in favor of Helsinn Healthcare S.A. in the patent infringement lawsuit for antiemetic agent ALOXI® (palonosetron hydrochloride) brought by Helsinn together with Roche Palo Alto LLC (Roche) against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. (collective...